Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

202 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-21

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

COVID-19 virus infection differs among people. Some people have no or mild symptoms. For others, COVID-19 is life threatening and causes damage to the body s organs. Researchers want to better understand the virus to learn how to kill it.

Objective:

To understand how the COVID-19 virus causes wide differences in how sick one can become from the infection.

Eligibility:

People ages 18-80 with COVID-19 infection

Design:

Participants will be screened with a review of their medical records.

Participants who enter the study at the beginning of their COVID-19 infection will stay in the hospital until they are healthy enough to go home. Those who enter after they have recovered may need to stay in the hospital 1-2 nights to perform the study tests.

Participants will have MRI and CT scans of the brain, heart, and lungs. They will lie in a machine that takes pictures of the body. For the MRI, soft padding or a coil will be placed around their head and chest. They may receive a dye injected into a vein.

Participants will have an ultrasound of the kidneys and heart.

Participants will provide blood and urine samples. They will provide nasal swabs.

Participants will have a bronchoscopy. A thin tube will be placed through the nose or mouth into the airway. Saltwater will be squirted into the lungs and removed by suction.

Participants may provide a spinal fluid sample. A needle injected into the spinal canal will obtain fluid.

Participants will have lung and heart function tests.

At various points after recovery, participants will repeat many of these tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac Imaging in SARS-CoV-2 (COVID-19)

NCT04403607

COVID

UNKNOWN

Multimodal IMAgery Characterization of Cardiac Damage and Severity After COVID-19 Infection

NCT04753762

COVID-19 Virus Disease Cardiac Complication

COMPLETED

Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR)

NCT04864899

Covid19 Viral Respiratory Infection

COMPLETED NA

Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors

NCT05164744

COVID-19 Pneumonia COVID-19 COVID-19 Respiratory Infection +4 more

RECRUITING

Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked

NCT04455347

COVID-19 Infection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description: This protocol will enroll patients within a 50 mile radius of Bethesda, Maryland, to the Clinical Center in a longitudinal study using granular clinical observations including pulmonary and cardiac functional assessments, comprehensive immunologic evaluations, and innovative imaging. Sequential analysis of blood, bronchoalveolar lavage, and spinal fluid, with simultaneous serial imaging can provide insights into mechanisms associated with the initiation, progression and resolution of organ dysfunction and systemic inflammation due to COVID-19 infection.

Objectives:

Primary objective:

To link inflammatory responses present in blood, bronchoalveolar lavage, spinal fluid, and with imaging of COVID-19 target organs (lungs, heart and brain) during the earliest stages of infection and at subsequent time points as the infection and host responses evolve, through recovery.

Secondary objectives

Assess the long-term effects of COVID-19 infection on immunologic, neurologic, cardiac and pulmonary function

Endpoints:

1. Measure inflammatory responses present in blood, bronchoalveolar lavage, and spinal fluid during the course of COVID-19 infection
2. Obtain imaging of target organs during the course of COVID-19 infection
3. Evaluate long-term effects of COVID-19 infection on immunologic, cardiac, pulmonary and neural function

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute and Long Term Effects of COVID-19 on Systemic Inflammation Acute and Long Term Effects of COVID-19 on Lung Function Acute and Long Term Effects of COVID-19 on Cardiac Function Acute and Long Term Effects of COVID-19 on Kidney Function Acute and Long Term Effects of COVID-19 on Brain Function

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acutely illl subjects

COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence

No interventions assigned to this group

Recovered subjects

COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Subjects within 1-28 days of documented COVID-19 infection for acute care:

* Stated willingness to comply with all study procedures and availability for the duration of the study
* Male or female, aged 18 to 80 years

* Only a minority of children and adolescents have been described as developing serious illness with COVID-19 infection. As such, this is not an age group at significant risk from complications due to this infection. Adults older than 80 years of age represent a group with the greatest risk of mortality from COVID-19 infection. The presence of significant co-morbidities requiring care that cannot be

provided at the CC would present a disadvantage to them to have their acute care provided for in the CC.

* Documentation of positive SARSCoV-19 test by nucleic acid detection (COVID-19 infection , RT-PCR)
* Ability of subject to understand and the willingness to sign a written informed consent document.

Subjects during recovery phase of the acute illness (day 28 +/- 7 days to 12 weeks) and convalescent phase (Week 13 up to 12 months), Year 2 convalescent phase (13 24 months), Year 3 convalescent phase (25 36 months) after recovery if care has been received at a facility outside of NIH:

* Stated willingness to comply with all study procedures and availability for the duration of the study.
* Male or female, aged 18 to 80 years.
* Study participants will be invited to continue their participation in the study in years 2 and 3 based on the results of their tests from the first year and their willingness to continue for the two additional years. If test results of imaging, blood, pulmonary function and or bronchoscopy have returned to normal at the end of one year, the need for further cardiopulmonary testing will be assessed for each patient. Anyone who is invited to continue in the 2nd and 3rd years may discontinue their participation at any time.

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

* Pregnancy or lactation Study participants who are enrolled in the study and become pregnant during the enrollment period will be discontinued from further study participation. Exposure to radiation or radiographic contrast agents for research purposes .only would not be warranted for a pregnant woman and her fetus.
* Serious mental illness (e.g. schizophrenia, manic depression) that would limit the ability of the participant to participate willingly into the study.

\-- The conduct of the study requires participation in studies that may be unduly stressful (e.g. MRI, bronchoscopy).
* Severe claustrophobia that would prohibit the conduct of imaging by MRI even if sedation is provided.
* Cardiac pacemaker or implantable defibrillator unless it is safe for MRI
* Cerebral aneurysm clip unless it is safe for MRI
* Brain stimulator (e.g. TENS-Unit) unless it is safe for MRI
* Any type of ear implant unless it is safe for MRI
* Foreign body in the eye (e.g. metal shavings)
* Metal shrapnel or bullet
* Any implanted device (e.g. insulin pump, drug infusion device
* Patients requiring mechanical ventilation at an outside hospital prior to transfer. Transporting these patients adds risk to their care.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No